Benzinga's Volume Movers

shares climbed 47.87 percent to $12.48. The volume of Lexicon Pharmaceuticals shares traded was 5401 percent higher than normal. Lexicon Pharmaceuticals reported that its TELESTAR Phase 3 clinical trial met primary endpoint.

surged 2.20 percent to $138.95. The volume of Partnerre shares traded 511 percent higher than normal. EXOR announced its plans to acquire outstanding shares of PartnerRe in a $6.9 billion deal.

shares moved up 3.51 percent to $20.96. The volume of Loxo Oncology traded was 165 percent higher than normal. Loxo Oncology is expected to announce Q2 financial results on August 5, 2015.

shares rose 4.60 percent to $20.70. The volume of TAL International shares traded was 163 percent higher than normal. TAL International shares have dropped 54.28 percent over the past 52 weeks, while the S&P 500 index has gained 8.50 percent in the same period.